Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.

Published on Mar 25, 2021in British Journal of Cancer5.791
· DOI :10.1038/S41416-020-01234-4
Rajiv Dave14
Estimated H-index: 14
(University of Manchester),
RV Dave3
Estimated H-index: 3
(University of Manchester)
+ 19 AuthorsB-MaP-C study collaborative
Sources
Abstract
The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.
References25
Newest
#1P.J. Lewis (Royal College of Radiologists)H-Index: 2
#2T. Roques (Royal College of Radiologists)H-Index: 1
5 CitationsSource
#1Alona Courtney (Imperial College London)H-Index: 3
#2Rachel O'Connell (The Royal Marsden NHS Foundation Trust)H-Index: 9
Last. Rajiv DaveH-Index: 14
view all 19 authors...
Abstract Introduction Approximately 55000 women in the United Kingdom are diagnosed with new breast cancer annually. Since emerging in December 2019, SARS-CoV-2 (coronavirus disease 2019, COVID-19) has become a global pandemic, affecting healthcare delivery worldwide. In response to the pandemic, multiple guidelines were issued to assist with rationalising breast cancer care. The primary aim of the B-MaP-C study is to audit and describe breast cancer management of patients newly diagnosed with b...
2 CitationsSource
#1Li Zhang (HUST: Huazhong University of Science and Technology)H-Index: 64
#1Li Zhang (HUST: Huazhong University of Science and Technology)H-Index: 9
Last. Min Zhou (HUST: Huazhong University of Science and Technology)H-Index: 70
view all 18 authors...
Background Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic. To date, the clinical characteristics of COVID-19-infected cancer patients are largely unknown. Patients and methods In this retrospective cohort study, we included cancer patients with laboratory confirmed COVID-19 from three designated hospitals in Wuhan, China. The clinical data were collected from medical records from Jan 13, 2020, to Feb 26, 2020. Univariate and ...
595 CitationsSource
#1Lennard Y W Lee (University of Birmingham)H-Index: 6
#2Jean-Baptiste Cazier (University of Birmingham)H-Index: 39
Last. Gary Middleton (University of Birmingham)H-Index: 50
view all 39 authors...
Summary Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with can...
311 CitationsSource
#1Mitch Dowsett (The Breast Cancer Research Foundation)H-Index: 124
#2Matthew J. Ellis (BCM: Baylor College of Medicine)H-Index: 97
Last. Nadia HarbeckH-Index: 80
view all 19 authors...
Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of patients who may have insufficiently endocrine-sensitive tumors and should be prioritised for early surgery or neoadjuvant chemotherapy rather than NeoET during or in the aftermath of the COVID-19 pande...
4 CitationsSource
#1Jill R. Dietz (Case Western Reserve University)H-Index: 6
#2Meena S. Moran (Yale University)H-Index: 34
Last. Katharine Yao (NorthShore University HealthSystem)H-Index: 28
view all 19 authors...
The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority l...
103 CitationsSource
#1A.M. Brunt (Keele University)H-Index: 12
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. John R Yarnold (The Royal Marsden NHS Foundation Trust)H-Index: 1
view all 46 authors...
Summary Background We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial. Methods FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring h...
103 CitationsSource
#1Annemarie B Docherty (Edin.: University of Edinburgh)H-Index: 19
#2Ewen M Harrison (Edin.: University of Edinburgh)H-Index: 33
Last. Isaric C InvestigatorsH-Index: 7
view all 25 authors...
Abstract Objective To characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and to explore risk factors associated with mortality in hospital. Design Prospective observat...
950 CitationsSource
Background The COVID-19 pandemic has disrupted routine hospital services globally. This study estimated the total number of adult elective operations that would be cancelled worldwide during the 12 weeks of peak disruption due to COVID-19. Methods A global expert response study was conducted to elicit projections for the proportion of elective surgery that would be cancelled or postponed during the 12 weeks of peak disruption. A Bayesian β-regression model was used to estimate 12-week cancellati...
327 CitationsSource
#1Evandro de Azambuja (ULB: Université libre de Bruxelles)H-Index: 60
#2Dario Trapani (IEO: European Institute of Oncology)H-Index: 16
Last. Giuseppe Curigliano (IEO: European Institute of Oncology)H-Index: 74
view all 13 authors...
The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency ...
22 CitationsSource
Cited By0
Newest